122 related articles for article (PubMed ID: 19184238)
1. Endogenous NIS expression in triple-negative breast cancers.
Renier C; Yao C; Goris M; Ghosh M; Katznelson L; Nowles K; Gambhir SS; Wapnir I
Ann Surg Oncol; 2009 Apr; 16(4):962-8. PubMed ID: 19184238
[TBL] [Abstract][Full Text] [Related]
2. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.
Willhauck MJ; Sharif-Samani B; Senekowitsch-Schmidtke R; Wunderlich N; Göke B; Morris JC; Spitzweg C
Breast Cancer Res Treat; 2008 May; 109(2):263-72. PubMed ID: 17636401
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
4. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC
Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050
[TBL] [Abstract][Full Text] [Related]
5. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid.
Wapnir IL; Goris M; Yudd A; Dohan O; Adelman D; Nowels K; Carrasco N
Clin Cancer Res; 2004 Jul; 10(13):4294-302. PubMed ID: 15240514
[TBL] [Abstract][Full Text] [Related]
6. Sodium iodide symporter, estrogen receptor, and progesterone receptor expression in carcinoma breast--an immunohistochemical analysis.
Tandon A; Shrivastava A; Kumar A; Prayaga AK; Sundaram C; Godbole MM
Indian J Pathol Microbiol; 2011; 54(4):745-51. PubMed ID: 22234102
[TBL] [Abstract][Full Text] [Related]
7. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
8. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of transcriptional activity of the oestrogen receptor with sodium iodide symporter as an imaging reporter gene.
Kang JH; Chung JK; Lee YJ; Kim KI; Jeong JM; Lee DS; Lee MC
Nucl Med Commun; 2006 Oct; 27(10):773-7. PubMed ID: 16969258
[TBL] [Abstract][Full Text] [Related]
10. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
Bao G; Yang DQ; Zhou B; Liu P; Wang S; Cheng L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2843-5. PubMed ID: 18167290
[TBL] [Abstract][Full Text] [Related]
11. Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients.
Florena AM; Tripodo C; Guarnotta C; Ingrao S; Porcasi R; Martorana A; Lo Bosco G; Cabibi D; Franco V
Pathobiology; 2007; 74(6):317-22. PubMed ID: 18087195
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer.
Scholz IV; Cengic N; Baker CH; Harrington KJ; Maletz K; Bergert ER; Vile R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2005 Feb; 12(3):272-80. PubMed ID: 15510175
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal immunohistochemical expression of sodium/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis.
Jung YH; Hah JH; Sung MW; Kim KH; Cho SY; Jeon YK
Laryngoscope; 2009 Mar; 119(3):541-8. PubMed ID: 19235753
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of adenovirus-mediated sodium iodide symporter gene in MCF-7 breast cancer cells with retinoic acid treatment.
Lim SJ; Paeng JC; Kim SJ; Kim SY; Lee H; Moon DH
J Nucl Med; 2007 Mar; 48(3):398-404. PubMed ID: 17332617
[TBL] [Abstract][Full Text] [Related]
15. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.
Jung KH; Paik JY; Ko BH; Lee KH
J Nucl Med; 2008 Dec; 49(12):1966-72. PubMed ID: 18997042
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy of triple-negative breast cancer.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells.
Unterholzner S; Willhauck MJ; Cengic N; Schütz M; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2006 Jan; 91(1):69-78. PubMed ID: 16234306
[TBL] [Abstract][Full Text] [Related]
19. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
20. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
